Patents by Inventor Jay P. Morgenstern

Jay P. Morgenstern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6025162
    Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: February 15, 2000
    Assignee: Immulogic Pharmaceutical Corporation
    Inventors: Bruce L. Rogers, Irwin J. Griffith, Jay P. Morgenstern
  • Patent number: 5939283
    Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Can f I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of peptides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.
    Type: Grant
    Filed: October 27, 1995
    Date of Patent: August 17, 1999
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Jay P. Morgenstern, Christine B. Bizinkauskas, Andrzej Koniecsny, Andrew W. Brauer
  • Patent number: 5891716
    Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Can f I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of petides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 6, 1999
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Jay P. Morgenstern, Andrzej Konieczny, Christine B. Bizinkauskas, Andrew W. Brauer
  • Patent number: 5843672
    Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Can f I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of peptides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 1, 1998
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Jay P. Morgenstern, Andrzej Konieczny, Christine B. Bizinkauskas, Andrew W. Brauer
  • Patent number: 5547669
    Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.
    Type: Grant
    Filed: December 13, 1991
    Date of Patent: August 20, 1996
    Inventors: Bruce L. Rogers, Jay P. Morgenstern, Julian F. Bond, Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Malcolm Morville